Pancreatic metastases

Pancreatic metastases are secondary deposits from extrapancreatic primary malignancies and account for a small proportion of malignant pancreatic masses, but their clinical relevance is increasing in an era of more intensive radiologic surveillance and longer survival in advanced cancer. In most cases, spread to the pancreas is hematogenous and reflects the ability of a tumor clone to arrest in the pancreatic microcirculation, extravasate and adapt to a complex glandular microenvironment rich in stroma, with distinctive oxygen gradients and a vascular architecture that, in certain histologic subtypes, may favor hypervascular lesion patterns. Topographically, metastases may involve any portion of the gland, with variable presentations according to their location, disease volume and relationship to the pancreatic duct and bile duct.

The natural history of pancreatic metastases is heterogeneous and depends critically on the histologic subtype of the primary tumor, the interval since the initial diagnosis, the presence or absence of extrapancreatic disease and the availability of effective systemic therapies. A clinically important distinctive feature is that some malignancies, particularly renal cell carcinoma, may metastasize to the pancreas many years after treatment of the primary tumor, sometimes with a relatively indolent course and isolated or predominant pancreatic involvement. In other settings, pancreatic metastases occur within rapidly progressive, aggressive systemic dissemination, with profoundly different prognostic and therapeutic implications.

Management requires a multidisciplinary approach integrating medical oncology, gastroenterology, radiology, pathology and pancreatic surgery. The objective is not only to recognize the metastatic nature of the lesion but also to place it correctly within the overall disease trajectory: in some patients the diagnosis changes the systemic strategy, whereas in others it opens the possibility of selected local treatments intended to provide prolonged control. The quality of clinical decision-making depends on diagnostic accuracy, characterization of the primary tumor and a realistic estimate of the expected benefit relative to the risks of invasive procedures and therapy.

Epidemiologically, pancreatic metastases are considered rare. In clinical and radiologic series they account for a limited fraction of malignant pancreatic neoplasms and diagnosed pancreatic masses, whereas autopsy studies in patients with advanced cancer show higher rates, consistent with historical clinical underdiagnosis and the fact that many pancreatic deposits remain asymptomatic or are not investigated during life. Estimates vary according to the setting, access to imaging and, above all, the intensity of radiologic follow-up in different oncologic pathways. In contemporary practice, routine CT and MRI surveillance, together with the greater sensitivity of multiparametric techniques, has increased detection of small and potentially resectable lesions, changing the distribution of observed cases.

The primary tumor most frequently associated with pancreatic metastases is renal cell carcinoma, which predominates in surgical series and numerous reviews, followed, with varying frequency, by lung carcinoma, colorectal tumors, melanoma and breast malignancies. In practical terms, the epidemiologic profile also depends on clinical selection: renal cell carcinoma often predominates in series of pancreatic resections for metastases because it may present with isolated or oligometastatic pancreatic disease and long disease-free intervals, conditions that make a local strategy more plausible. In nonsurgical settings dominated by widespread systemic disease, the distribution of primary tumors may differ, with a greater contribution from lung and colorectal cancers.

Latency is a distinctive epidemiologic and clinical feature. In renal cell carcinoma in particular, a pancreatic metastasis may appear after a long interval following treatment of the primary tumor and may present as a single lesion or as multiple lesions distributed throughout the parenchyma, sometimes with a relatively indolent course compared with metastases at other sites. This feature has important practical consequences: in a patient with a remote history of renal cell carcinoma, a pancreatic mass should not automatically be interpreted as a primary pancreatic adenocarcinoma, because diagnostic error would substantially affect prognosis, treatment and the sequence of investigations.

The risk factors for pancreatic metastases cannot be expressed as environmental or behavioral factors, because the condition is a secondary manifestation of primary tumors. The main determinants relate to the biologic profile of the histologic subtype of origin, its ability to disseminate hematogenously, survival duration and the control of extrapancreatic disease achieved with systemic therapy. In particular, prolonged survival with metastatic disease, effective control of specific sites and the emergence of oligometastatic patterns make it more likely that the pancreas will be identified as a site of progression or late relapse.

Clinically, a positive history of tumors known to metastasize to the pancreas—especially renal cell carcinoma and melanoma—and the presence of hypervascular lesions on imaging increase the pretest probability. Detection of isolated or predominant pancreatic metastases, particularly from renal cell carcinoma, also suggests distinctive tumor biology and requires dedicated assessment, because the strategy may differ profoundly from that for rapidly progressive systemic dissemination. Thus, the epidemiology of pancreatic metastases is defined not only by absolute frequencies but also by characteristic clinical trajectories that must be recognized to avoid presumptive diagnoses and guide the diagnostic pathway appropriately.

Pancreatic metastases are not subject to population screening programs because they result from dissemination of primary tumors rather than being a primary disease preventable through public-health strategies. Primary prevention corresponds to prevention of the tumors of origin and to the effectiveness of systemic treatments in reducing the risk of metastatic spread. In clinical practice, the relevant concept is targeted surveillance, meaning early identification of pancreatic deposits in patients with malignancies at high risk of pancreatic metastasis or in long-term survivors for whom follow-up imaging is an integral part of the oncologic pathway.

Most pancreatic metastases are identified incidentally during staging examinations or treatment reassessment performed for the primary tumor. This is clinically relevant: the probability of early diagnosis is higher in pathways characterized by serial imaging, and the absence of symptoms does not exclude clinically significant disease. Surveillance is therefore not uniform across all tumors, but results from the combination of biologic risk and the intensity of monitoring already indicated for the underlying malignancy.

In some scenarios, diagnosis of a pancreatic metastasis materially changes the therapeutic strategy. In patients with controlled disease and suspected isolated or oligometastatic pancreatic involvement, early identification may open selected local options or prompt a change in systemic therapy. In patients with active systemic disease, however, the finding is often important chiefly for correct etiologic attribution of the pancreatic mass and for avoiding unnecessary invasive pathways or inappropriate local treatment.

A practical aspect of targeted surveillance is management of the potential diagnostic confusion with primary pancreatic neoplasms, particularly ductal adenocarcinoma and neuroendocrine tumors. Surveillance therefore entails a low threshold for further investigation when a new pancreatic lesion is identified in a patient with cancer, especially when its radiologic appearance is atypical for ductal adenocarcinoma or the natural history of the primary tumor makes a late metastasis plausible. In summary, targeted surveillance does not indiscriminately seek “metastases in the pancreas”; it aims to recognize a potentially metastatic lesion early when the clinical context suggests that the result of the work-up may change decisions and goals of care.

Metastasis to the pancreas is the outcome of a complex, selective biologic cascade. Tumor cells must acquire the ability to invade locally, enter the vasculature, survive in the bloodstream and arrest in the pancreatic microcirculation, followed by extravasation and adaptation to the glandular microenvironment. Only a minute fraction of circulating tumor cells completes the entire process, and the rarity of pancreatic metastases reflects, at least in part, the high degree of selection required for stable colonization of this site.

Interaction with the endothelium and pancreatic stroma is a key step. The pancreas has a complex stromal architecture rich in extracellular matrix and resident immune cells, within which the metastatic niche must be established or “educated” by the tumor. Metastatic growth depends on the balance among prosurvival signaling, local angiogenesis, stromal remodeling and the ability to evade or modulate the immune response in the microenvironment. This concept is clinically relevant because it helps explain differences in radiologic appearance and growth patterns among histologic subtypes.

Some primary tumors have a particular propensity to produce pancreatic metastases with distinctive vascular characteristics. Renal cell carcinoma, for example, is often associated with hypervascular pancreatic metastases on imaging, a feature reflecting prominent angiogenic programs and carrying diagnostic and procedural implications. Vascularity contributes both to radiologic appearance and to bleeding risk during invasive procedures, making careful planning of the diagnostic pathway essential for safety and sampling yield.

From an evolutionary perspective, metastases may diverge biologically from the primary tumor, retaining founding alterations while acquiring adaptations selected within the new niche. This heterogeneity explains why, in some patients, the clinical course is dominated by selective progression at particular sites and why characterization of the metastatic lesion, when available, may have practical implications for systemic treatment selection. Overall, pancreatic colonization is not merely deposition of tumor cells but a process of adaptation and selection that produces widely differing clinical behaviors across histologic subtypes and patients.

The clinical presentation of pancreatic metastases varies according to location, size, relationship to the pancreatic duct and bile duct, and the presence of extrapancreatic disease. A substantial proportion of patients are asymptomatic and the lesion is identified incidentally during surveillance or staging imaging for the primary tumor. This scenario is particularly common in structured follow-up pathways and underscores that absence of symptoms does not imply clinical irrelevance, because the lesion may still require diagnostic characterization to guide the oncologic strategy correctly.

When symptomatic, pancreatic metastases may mimic primary pancreatic neoplasms. Patients may report epigastric or back pain, weight loss, fatigue and reduced appetite, usually with a subacute course. Lesions in the pancreatic head may cause obstructive jaundice through compression or infiltration of the bile duct, with dark urine, pale stools and pruritus, producing a clinical picture that requires prompt assessment for both diagnosis and management of biliary obstruction. Lesions in the body and tail are more often paucisymptomatic and may be diagnosed later or detected during follow-up.

A particularly important presentation is acute or recurrent pancreatitis caused by ductal obstruction or impaired pancreatic drainage near the lesion, which may lead to urgent evaluation. In such cases, the oncologic history—even if remote—is crucial for correct interpretation and for avoiding presumptive attribution of the mass to a primary pancreatic tumor. Other patients may develop signs of exocrine pancreatic insufficiency or worsening glycemic control, especially when disease involves a large portion of the gland or systemic treatments affecting metabolism and pancreatic function are also present.

Physical findings may be subtle or absent in the early stages. Obstructive jaundice may produce scleral and cutaneous icterus and signs of cholestasis; significant pain may be associated with epigastric tenderness, whereas advanced disease may present with general deterioration and sarcopenia. Clinical evaluation should follow a coherent sequence: detailed oncologic history, including the interval since the primary tumor and previous treatments; assessment of abdominal and systemic symptoms; examination for signs of cholestasis or complications; and integration with clinical data on extrapancreatic disease. This approach is essential because a pancreatic metastasis is not an isolated event but one component of an overall oncologic picture that determines prognosis and therapeutic choices.

The diagnostic work-up for pancreatic metastases should be a progressive, coherent process designed to distinguish a secondary lesion from a primary pancreatic tumor and, above all, to establish the histology and biologic profile needed to plan systemic therapy and any local treatment. Suspicion arises in three main scenarios: incidental detection of a pancreatic mass in a patient undergoing cancer follow-up; development of symptoms consistent with biliary compression or ductal obstruction; and identification of a pancreatic lesion during the work-up of a malignancy of unknown primary. In each case, the diagnostic logic begins with clinical and laboratory assessment, proceeds to high-quality dedicated imaging and culminates, when indicated, in cytologic-histologic confirmation with appropriate immunohistochemical and molecular integration.

After targeted history and physical examination, laboratory tests are used primarily to assess complications and differential diagnoses rather than establish etiology. Biochemical cholestasis with increased bilirubin and alkaline phosphatase suggests compression of the common bile duct or infiltration near the pancreatic head; amylase and lipase may be elevated with ductal obstruction or associated pancreatitis. Serum tumor markers such as CA 19-9 and CEA lack sufficient specificity to distinguish metastases from pancreatic ductal adenocarcinoma and, when elevated, must be interpreted in the overall clinical context and according to the known primary histologic subtype. In patients with systemic symptoms or fever, the work-up must also consider infectious or inflammatory processes that may mimic pancreatic masses, particularly in the setting of cancer-related immunosuppression.

The first-line imaging study for anatomic characterization is contrast-enhanced abdominal CT using a multiphasic pancreatic protocol. It defines lesion size and location, vascular relationships, multiplicity, possible duodenal or biliary infiltration and the extent of extrapancreatic metastatic disease. A useful radiologic feature is that some metastases, particularly from renal cell carcinoma, tend to be hypervascular in arterial phases, whereas primary ductal adenocarcinoma is more often hypovascular. No enhancement pattern is pathognomonic, however, and overlap with neuroendocrine tumors, focal pancreatitis or histologic variants of primary neoplasms always requires cautious interpretation. MRI with magnetic resonance cholangiopancreatography (MRCP) is useful for ductal characterization, distinguishing extrinsic compression from infiltration and assessing small or equivocal lesions, while providing additional information on diffusion and cystic components.

Endoscopic ultrasonography (EUS) is a decisive diagnostic step because it combines high sensitivity for small lesions with the ability to obtain tissue by fine-needle aspiration (FNA) or core-needle biopsy (FNB). In contemporary practice, acquisition of adequate material for cell block, immunohistochemistry and, when needed, molecular comparison with the primary tumor makes EUS-FNA/FNB the preferred method when the diagnosis will change treatment. Sampling is particularly important when the pancreatic mass is the first manifestation of cancer, when imaging is atypical or when local treatment options require histologic certainty.

Pathologic assessment has two objectives: to confirm the metastatic nature of the lesion and to identify the site of origin accurately or, in patients with a known primary tumor, to verify biologic concordance and clinically relevant divergence. Immunohistochemistry is often decisive: PAX8 and compatible profiles support renal cell carcinoma; TTF-1 and Napsin A suggest lung origin; GATA3 and hormone receptors may support breast origin in the appropriate context; SOX10 and S100 suggest melanocytic lineage; and CDX2 and CK20 may support intestinal origin, whereas neuroendocrine profiles require integration with morphology, proliferative index and specific markers. When available, molecular comparison with the primary tumor or prior specimens can strengthen diagnostic certainty and guide targeted therapy or immunotherapy.

18F-FDG PET is a complementary tool, not a universally required examination. It is useful in cancers of unknown primary, when the primary site or other potentially accessible metastatic sites must be identified, and in some histologic subtypes in which metabolic activity facilitates disease mapping. In other settings, particularly known tumors with already conclusive imaging, PET adds value only if it changes the treatment plan. Systemic staging with chest, abdominal and pelvic imaging and subtype-specific assessments is always essential, because management of a pancreatic metastasis cannot be separated from control of extrapancreatic disease and the overall disease burden.

The differential diagnosis primarily includes pancreatic ductal adenocarcinoma, pancreatic neuroendocrine tumors, autoimmune or focal pancreatitis, lymphoma, metastases from other primary tumors and, less commonly, rare cystic or solid neoplasms. Correct distinction is not merely formal: it determines systemic treatment, the indication for surgery or endoscopic procedures and the follow-up strategy. Therefore, when the diagnosis remains uncertain after imaging, EUS-guided tissue confirmation should be considered an integral rather than optional part of the work-up.

Pancreatic metastases do not have an independent anatomic staging system because they represent systemic dissemination and prognosis is dominated by the primary histologic subtype and overall disease distribution. Clinical stratification must therefore integrate patient variables, characteristics of the pancreatic lesion and, above all, the trajectory of the tumor of origin. In practical terms, the first prognostic distinction is between an isolated or predominant pancreatic metastasis and pancreatic metastasis occurring within active polymetastatic disease. This distinction radically affects treatment intent, ranging from local strategies potentially capable of prolonging control to a predominantly systemic and symptom-oriented approach.

Latency interval: the interval between diagnosis of the primary tumor and development of pancreatic metastasis is a crucial clinical parameter. In some malignancies, particularly renal cell carcinoma, pancreatic metastases may appear many years after nephrectomy, often with a relatively indolent course and sometimes with pancreatic tropism. A long interval is frequently interpreted as an indicator of less aggressive biology and may identify candidates for resection or other local approaches, provided that the remainder of the disease is controllable.

Intrapancreatic distribution influences both functional prognosis and the feasibility of local treatment. Unifocal lesions in the body or tail may be treated with distal resection in selected settings; lesions in the head are more likely to cause obstructive jaundice and require more complex procedures. Intrapancreatic multifocality, described particularly in renal cell carcinoma metastases, does not automatically preclude surgery but increases surgical complexity and the risk of postoperative endocrine and exocrine insufficiency, making rigorous selection essential.

Systemic disease burden and control of extrapancreatic disease are dominant determinants. A pancreatic metastasis in a patient with rapidly progressive multiorgan disease generally has a different prognostic meaning from an isolated lesion found during follow-up, and treatment must be consistent with life expectancy and the systemic options available for that tumor. Performance status, frailty, comorbidities and pre-existing pancreatic reserve also affect the risk-benefit ratio of invasive procedures.

In practical terms, prognostic assessment should always culminate in a multidisciplinary synthesis defining the feasibility of systemic disease control with medical therapy, the indication for local treatment for symptom relief or prolonged control, and the anticipated risks in terms of complications, metabolic sequelae and effects on quality of life. In this setting, histology and immunophenotype are not merely descriptive but essential components of stratification because they define sensitivity to targeted therapies and immunotherapy and therefore the true likelihood of transforming a pancreatic metastasis into a condition controllable over the medium to long term.

Treatment of pancreatic metastases requires an integrated approach combining systemic therapy directed at the primary tumor, endoscopic or surgical management of complications and, in selected subgroups, local strategies intended to provide prolonged control. The decision must always begin with a realistic objective: disease control and preservation of function in patients with favorable biology and limited disease, or effective palliation in advanced dissemination. In every scenario, treatment selection is inseparable from complete systemic staging and a reliable histologic diagnosis.

Systemic therapy is the cornerstone of treatment in most patients because a pancreatic metastasis is, by definition, a manifestation of disseminated disease. Drug selection follows standards for the tumor of origin and depends on histologic subtype and biomarkers. In tumors with actionable molecular targets and highly effective drugs, the systemic response may reduce the need for local intervention, particularly when the pancreatic lesion is asymptomatic or minimally symptomatic. Close clinical and radiologic monitoring is essential in these cases to detect local progression with a risk of biliary obstruction or pancreatitis at an early stage.

Surgery has a selective but potentially important role, especially for isolated pancreatic metastases or oligometastatic disease in which control of extrapancreatic disease is achievable. The strongest evidence concerns renal cell carcinoma metastases, for which pancreatic resection in carefully selected patients has been associated with prolonged survival in surgical series and multicenter studies. Procedures include pancreaticoduodenectomy for lesions in the head, distal pancreatectomy for lesions in the body or tail, and central resections or enucleation in selected cases, with the choice guided by location, ductal relationships, multifocality and oncologic objectives. Resection may also provide diagnostic value and reduce the risk of local complications, but should be offered only when the expected benefit outweighs perioperative morbidity and permanent endocrine and exocrine sequelae.

Endoscopic procedures are essential for managing obstructive complications. In jaundice caused by compression or infiltration of the common bile duct, endoscopic biliary drainage with stent placement relieves cholestasis and pruritus, reduces infectious risk and permits continuation of systemic therapy. For duodenal obstruction, options include duodenal stenting or endoscopic or surgical gastrojejunostomy according to the clinical setting and life expectancy. When a metastasis causes recurrent pancreatitis through ductal obstruction, specialist assessment is required to balance drainage procedures, medical management and indications for local treatment.

Radiotherapy may be considered in selected settings for palliation, pain control or reduction of unresectable tumor bulk, or as an adjunct in cases of uncontrolled bleeding or local compression. The decision depends on the radiosensitivity of the primary tumor, clinical objectives and tolerability. In patients with hypervascular metastases or bleeding risk, planning must be particularly cautious and coordinated with other supportive measures.

An essential component of treatment is management of functional sequelae and symptoms. Pain control, nutritional therapy, treatment of maldigestion with pancreatic enzymes and early diagnosis of diabetes or glycemic decompensation are integral to the approach because disease and treatment—especially surgery—may significantly impair endocrine and exocrine function. In patients considered for resection, preoperative assessment should include metabolic risk and strategies to prevent postoperative complications.

Follow-up of pancreatic metastases should be individualized and based on two principles: surveillance of systemic disease according to standards for the primary tumor and specific monitoring for pancreaticobiliary complications, which may emerge even when disease is radiologically stable. In patients receiving systemic therapy, follow-up CT or MRI using consistent protocols permits assessment of response, stability and progression, with particular attention to new cholestasis, ductal dilatation or signs of subclinical pancreatitis.

After pancreatic resection for metastases, follow-up should include oncologic surveillance for local and systemic recurrence and a structured program of metabolic and nutritional monitoring. The risk of diabetes and exocrine pancreatic insufficiency depends on the type of resection and pre-existing reserve; glucose monitoring, weight assessment, symptoms of malabsorption and adjustment of pancreatic enzyme replacement should therefore be incorporated into routine care. After more extensive pancreatectomy, follow-up often requires a multidisciplinary pathway involving endocrinology and clinical nutrition.

In patients who have undergone endoscopic procedures, surveillance focuses on patency of biliary or duodenal stents, risk of cholangitis, post-procedural pancreatitis and the need for scheduled replacement according to device type. Fever, abdominal pain, worsening jaundice or increased cholestatic indices should be regarded as signs of possible drainage dysfunction and prompt reassessment. In all cases, follow-up intensity should reflect the biology of the primary tumor and the expected risk of progression, avoiding rigid schedules while maintaining a low threshold for imaging when symptoms compatible with local complications appear.

Quality of life in patients with pancreatic metastases is determined by the interaction among systemic disease burden, risk of pancreaticobiliary complications, toxicity of systemic therapy and sequelae of local treatment. In patients with prolonged survival, especially those with more slowly growing histologic subtypes or effective treatments, preservation of metabolic and functional capacity becomes a central objective and should be addressed proactively rather than reactively.

A common determinant of impaired quality of life is symptom burden from cholestasis and biliary obstruction, including pruritus, fatigue, sleep disturbance and risk of biliary infection. Successful endoscopic or surgical drainage often produces an immediate improvement in well-being and allows oncologic therapy to continue. Similarly, abdominal and back pain may result from local compression or associated pancreatitis and requires a structured, stepwise analgesic approach combined with treatment of the mechanical cause when present.

Endocrine and exocrine sequelae are particularly relevant after pancreatic resection or with substantial parenchymal infiltration. Secondary diabetes, which may be unstable, can develop or worsen and requires therapeutic education, monitoring and treatment adjustment. Exocrine insufficiency with steatorrhea, weight loss and nutritional deficiencies requires pancreatic enzyme replacement, dietary optimization and nutritional follow-up. These issues directly affect energy, independence and tolerance of oncologic treatment.

Quality of life is also influenced by psychological factors and prognostic uncertainty. Detection of a metastasis in an organ perceived as critical, such as the pancreas, may generate intense anxiety even when the biology of the primary tumor is favorable and effective treatment options exist. Accessible psycho-oncologic support, together with clear and consistent communication regarding goals of care, reduces emotional burden and improves adherence.

For patients with surgical sequelae, rehabilitation and education in managing metabolic consequences are essential components of care. Even when oncologic control is achieved, quality of life may be impaired by fatigue, dietary changes, the need for enzyme replacement and diabetes management. Multidisciplinary follow-up integrating oncology, surgery, gastroenterology, endocrinology and nutrition is often the most effective strategy for maintaining independence and long-term well-being.

Complications of pancreatic metastases arise from both the local lesion and its treatment. Clinically, one of the most important is biliary obstruction, particularly with lesions in the pancreatic head or uncinate process, causing jaundice, cholangitis and functional hepatic impairment that may preclude systemic therapy. Obstruction may progress and often requires endoscopic stent drainage, sometimes repeatedly because of dysfunction or occlusion. A related risk is biliary infection, which may become severe in immunocompromised patients.

Pancreatitis may arise from pancreatic duct obstruction, endoscopic procedures or as a complication of some systemic treatments. It may present with acute pain and elevated pancreatic enzymes and, in severe cases, local or systemic complications. In patients with recurrent pancreatitis, assessment should identify the obstructive mechanism and balance drainage, medical therapy and indications for local treatment.

Bleeding is less common but potentially serious, particularly with hypervascular metastases, vascular invasion, secondary duodenal ulceration or invasive procedures. Management may require endoscopy, interventional radiology or surgery according to the site and hemodynamic stability. In patients requiring anticoagulation for thromboembolic comorbidities, hemorrhagic risk must be assessed carefully and reassessed dynamically.

Duodenal obstruction may result from compression or infiltration of the duodenum, causing vomiting, weight loss and dehydration. The choice between duodenal stenting and bypass depends on life expectancy, general condition and treatment objectives. Nutritional impairment is a common consequence, amplified by systemic disease and treatment, and requires early intervention.

When resection is indicated, postoperative complications may include pancreatic fistula, delayed gastric emptying, intra-abdominal infection, postoperative hemorrhage and endocrine and exocrine pancreatic insufficiency. Even with technically optimal surgery, loss of pancreatic parenchyma may cause diabetes and maldigestion with lasting consequences. These sequelae are not merely adverse effects but structural considerations that must inform preoperative decision-making and counseling.

• Complications of EUS-FNA/FNB: post-procedural pancreatitis, bleeding, infection and post-procedural pain.
• Complications of biliary stenting: cholangitis, stent occlusion, stent migration and post-ERCP pancreatitis.
• Complications of pancreatic resection: pancreatic fistula, infection, hemorrhage, delayed gastric emptying, diabetes and exocrine insufficiency.

Finally, a pancreatic metastasis may indicate complex tumor biology and clonal evolution, with the possibility of sudden systemic progression even after periods of stability. Prevention of complications therefore rests on active clinical surveillance, early management of signs of cholestasis or pancreatitis, nutritional optimization and multidisciplinary coordination, preserving access to effective oncologic treatment and maintaining the best possible quality of life.